Novo Slides as Amgen Fuels Obesity Drug Competition Fears

Novo Nordisk's stock took a hit as concerns grew over potential competition from Amgen in the obesity drug market. This reaction highlights the sensitivity of pharmaceutical stocks to competitive pressures in lucrative markets.